Logo Image

Anne Chiang, MD, PhD, Yale Cancer Center

Articles by Anne Chiang, MD, PhD, Yale Cancer Center

Treatment Considerations: Chemotherapy + IO in ES SCLC

ByHossein Borghaei, DO, MS, Fox Chase Cancer Center,Anne Chiang, MD, PhD, Yale Cancer Center,Wade Iams, MD, Vanderbilt University Medical Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Vivek Subbiah, MD, MD Anderson Cancer Center

Panelists reflect on key points from recent studies in ES SCLC by discussing patients for whom immunotherapy may be appropriate, examining the role of adding CTLA4 inhibition to a PD-L1 inhibitor, and reviewing factors to consider when deciding between cisplatin or carboplatin.

First-Line Therapy in ES SCLS: KEYNOTE-604

ByHossein Borghaei, DO, Fox Chase Cancer Center,Anne Chiang, MD, PhD, Yale Cancer Center,Wade Iams, MD, Vanderbilt University Medical Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Vivek Subbiah, MD, MD Anderson Cancer Center

Key opinion leader in lung cancer, Vivek Subbiah, MD, examines the phase 3 KEYNOTE-604 trial of platinum-based chemotherapy + pembrolizumab and considers whether the data support findings from other trials of chemotherapy + IO combination approaches.

First-Line Therapy in ES SCLC: CASPIAN

ByHossein Borghaei, DO, MS, Fox Chase Cancer Center,Anne Chiang, MD, PhD, Yale Cancer Center,Wade Iams, MD, Vanderbilt University Medical Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Vivek Subbiah, MD, MD Anderson Cancer Center

Thoracic oncologist, Anne Chiang, MD, PhD, reviews the trial design and results of the CASPIAN trial and emphasizes implications for long-term benefit of combining platinum chemotherapy with durvalumab.

First-Line Therapy in ES SCLC: IMpower133

ByHossein Borghaei, DO, MS, Fox Chase Cancer Center,Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center,Vivek Subbiah, MD, MD Anderson Cancer Center,Anne Chiang, MD, PhD, Yale Cancer Center,Wade Iams, MD, Vanderbilt University Medical Center

Stephen Liu, MD guides a discussion on recent updates on IO+chemotherapy combinations in extensive-stage small cell lung cancer by reviewing data from the phase 3 IMpower133 l trial of carboplatin/etoposide/atezolizumab.